Myology 2019, was the sixth edition of the international congress of myology organized by AFM-Telethon, took place in Bordeaux, France, from March 25 to 28.
More than 800 researchers and scientific experts from 35 countries worldwide gathered for the congress. This year’s congress consisted of seven plenary sessions, 12 parallel sessions, 5 industry symposiums. Over 400 scientific posters highlighted current issues related to myology, discoveries and new developments, progress in the identification of new genes, and innovative therapies including the latest developments in gene therapy for the treatment of the entire muscle mass.
The congress showed that we are entering in a new era for neuromuscular diseases, namely the era of therapeutics, whether they be innovative therapies derived from genetics or molecule repositioning. The hallmark of this congress was that it gathered both fundamental research and applied research with very talented and determined experts from around the globe. With new molecules, new mechanisms, new concepts, new approaches, new trials, new treatments and new hopes for pathologies which, until that time, had no prospect. Hope becomes a reality.
EURO-NMD helpdesk assistant Chloe attended on behalf of the ERN. A number of congress delegates who are affiliated with our network took this opportunity find out more about the Clinical Patient Management System, ask any questions they may have and receive a little one-to-one tuition on the system.
Find out more about this year’s congress from this specially made overview video in which Serge Braun discusses how beneficial this congress has been at this very exciting time within therapy development.
Further questions and answers about the background planning of this year’s congress
“Like all scientific congresses, it is a Scientific Committee, composed of international experts, which defines the priorities and the key themes of the meeting. Then, these themes are made available to the entire scientific community worldwide, among researchers and doctors/clinicians, who can, if they wish to present their work at the congress, either in the form of posters or oral presentations, after acceptance of the committee. This year, we received nearly 450 proposals for abstracts! score that shows the magnitude of our congress on the international scientific place.”
“This year, we proposed a whole new session: Lessons from Negative Therapeutic Trials. We spent a lot of time talking about things that work, and not enough of the failures we have encountered. Understanding any difficulties encountered are essential to surpass them and avoid duplication. This session was close to my heart and I am happy that it featured in this year’s congress.”
“I am, like all members of the organization, very impatient because we learn so much from each other in this kind of event, but also because we are starting new (beautiful) collaborations.” It is extremely enriching for our work and potential therapies, but also for our own culture as researchers. And then, as in any event such as this, there are many opportunities, such as chance meetings and meetings held on the sidelines of the congress who are incredibly rich in learning.”